

The University of Western Ontario
BIOLOGICAL AGENTS REGISTRY FORM
Approved Biohazards Subcommittee: October 14, 2011
Biosafety Website: www.uwo.ca/humanresources/biosafety/

This form must be completed by each Principal Investigator holding a grant administered by the University of Western Ontario (UWO) or in charge of a laboratory/facility where the use of Level 1, 2 or 3 biological agents is described in the laboratory or animal work proposed. The form must also be completed if any work is proposed involving animals carrying zoonotic agents infectious to humans or involving plants, fungi, or insects that require Public Health Agency of Canada (PHAC) or Canadian Food Inspection Agency (CFIA) permits.

This form must be updated at least every 3 years or when there are changes to the biological agents being used.

Containment Levels will be established in accordance with Laboratory Biosafety Guidelines, 3rd edition, 2004, Public Health Agency of Canada (PHAC) or Containment Standards for Veterinary Facilities, 1st edition 1996, Canadian Food Inspection Agency (CFIA).

Electronically completed forms are to be submitted to Occupational Health and Safety, (OHS), (Support Services Building, Room 4190 or to jstanle2@uwo.ca) for distribution to the Biohazards Subcommittee. For questions regarding this form, please contact the Biosafety Officer at extension 81135 or biosafety@uwo.ca. If there are changes to the information on this form (excluding grant title and funding agencies), contact Occupational Health and Safety for a modification form. See website: www.uwo.ca/humanresources/biosafety/.

Please ensure that all questions are fully and clearly answered. Failure to do so will lead to the form being returned, which will cause delays in your approval and frustration for you and your colleagues on the Committee.

If you are re-submitting this form as requested by the Biohazards Subcommittee, please make modifications to the form in bold print, highlighted in yellow. Please re-submit forms electronically.

PRINCIPAL INVESTIGATOR:	Rodney DeKoter
DEPARTMENT:	Microbiology & Immunology
ADDRESS:	Dental Sciences 3003
PHONE NUMBER:	(519) 661-2084
EMERGENCY PHONE NUMBER(S):	Cell phone (519) 902-2092
EMAIL:	rdekoter@schulich.uwo.ca

Location of experimental work to be carried out :

Building :	Dental Sciences 3003 (A-D)	Room(s):	
Building :		Room(s):	
Building :		Room(s):	

***For work being performed at Institutions affiliated with the University of Western Ontario, the Safety Officer for the Institution where experiments will take place must sign the form prior to its being sent to the University of Western Ontario Biosafety Officer (See Section 15.0, Approvals).**

FUNDING AGENCY/AGENCIES: CIHR, NSERC, Shriners Hospitals of America

GRANT TITLE(S):

- 1) "Functions of related ETS transcription factors in B cells" (CIHR)
- 2) "Graded Regulation of Gene expression by PU.1" (NSERC)
- 3) "The role of PU.1 in the generation of myeloid-derived suppressor cells after thermal injury" (Shriners)

UNDERGRADUATE COURSE NAME(IF APPLICABLE): _____

List all personnel working under Principal Investigators supervision in this location:

Name	UWO E-mail Address	Date of Biosafety Training
Renee Tamming	rtamming@uwo.ca	scheduled
Ali Abbas	aabbas6@uwo.ca	Spring 2011
Oren Zarnett	oren@zarnett.ca	Fall 2011

Rachel Ziliotto	rziliott@uwo.ca	Fall 2011
Shereen Turkistany	shereenturkistany@gmail.com	Spring 2011
Stephen Li	sli265@uwo.ca	Fall 2010
Darah Christie	dchrist8@uwo.ca	Fall 2008
Sherry Xu	lxu48@uwo.ca	Fall 2008

Please explain how the biological agents are used in your project and how they are stored and disposed of. The BARF without this description will not be reviewed.

We use the following types of biological agents in our laboratory: 1) Cells or tissues from genetically modified mice. 2) Cells or tissues from human samples. 3) Established cell lines from human or mouse sources. 3) Replication-incompetent retroviral vectors, and 4) Recombinant DNA technology using plasmids grown in the bacteria E. coli.

These agents are used in the laboratory or in a biological safety cabinet in accord with biosafety level 1 and 2 guidelines. Biological samples are disposed of by autoclaving or incineration. Plastic or glassware that is contaminated with biological agents is disposed of by autoclaving or overnight treatment with 10% bleach.

Primary tissues or established cell lines are stored in liquid nitrogen or in a -80 C freezer. Live cells are cultured in an incubator located in our cell culture room.

Our laboratory does not work with infectious microorganisms.

**Please include a ONE page research summary or teaching protocol in lay terms.
Forms with summaries more than one page will not be reviewed.**

Our laboratory studies gene regulation in the immune system. The long-term goal of our research is to determine how diseases of the immune system, including autoimmunity and leukemia, are controlled by proteins called transcription factors.

Our laboratory is working to elucidate the role of E26 transformation-specific (Ets) family transcription factors in B cells. We have recently investigated the function of PU.1, as well as two closely related Ets family members called Spi-B and Spi-C. PU.1 and Spi-B activate transcription of genes encoding several mediators of B cell receptor (BCR) signaling. Our experiments suggest that Spi-C opposes the activity of PU.1 and Spi-B in vitro and in vivo. Our long-term goal is to determine if Spi-C, PU.1, and Spi-B are involved in tolerance induction and autoimmune disease.

The second major project in our laboratory is to determine the genetic causes of leukemia, a cancer of white blood cells. Acute lymphoblastic leukemia (ALL) occurs most frequently in young children but can also occur in adults. In children ALL has a "cure" rate of 80%, yet enough children get this disease that it still represents a leading cause of cancer deaths. Furthermore, ALL in adults has a much poorer prognosis and a low cure rate. Our laboratory uses mice to model ALL so that we can understand the molecular mechanisms that underlie this disease. We recently discovered that two related proteins called PU.1 and Spi-B function as tumor suppressors. In other words, the function of these proteins is to prevent cancer, and conversely when the genes encoding these two proteins are deleted in mice, the result is an aggressive form of ALL. The long-term goal of this research is to identify potential new drug targets for ALL at the molecular level.

1.0 Microorganisms

1.1 Does your work involve the use of biological agents? YES NO
(non-pathogenic and pathogenic biological agents including but not limited to bacteria and other microorganisms, viruses, prions, parasites or pathogens of plant or animal origin)? If no, please proceed to Section 2.0

Do you use microorganisms that require a permit from the CFIA? YES NO

If YES, please give the name of the species _____

What is the origin of the microorganism(s)? _____

Please describe the risk (if any) of escape and how this will be mitigated:

Please attach the CFIA permit.

Please describe any CFIA permit conditions:

1.2 Please complete the table below:

Full Scientific Name of Biological Agent(s)* (Be specific)	Is it known to be a human pathogen? YES/NO	Is it known to be an animal pathogen? YES/NO	Is it known to be a zoonotic agent? YES/NO	Maximum quantity to be cultured at one time? (in Litres)	Source/Supplier	PHAC or CFIA Containment Level
<i>Replication-incomp. Ecotropic Retrovirus</i>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	0.5	N/Z	<input type="checkbox"/> 1 <input checked="" type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
<i>E.coli (cloning and subcloning strains)</i>	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No	2	See list attached to this form.	<input checked="" type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No	<input type="checkbox"/> Yes <input type="checkbox"/> No			<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3

**Please attach a Material Safety Data Sheet or equivalent from the supplier if the bacterium used is not on this link:*
http://www.uwo.ca/humanresources/docandform/docs/ohs/CFIA_Ecoli_list.pdf

Additional Comments: Hyperlinks to Material Safety Data Sheets are provided with the attached list.

2.0 Cell Culture

2.1 Does your work involve the use of cell cultures? YES NO
 (If NO, please proceed to Section 3.0)

2.2 Please indicate the type of primary cells (i.e. derived from fresh tissue) that will be grown in culture:

Cell Type	Is this cell type used in your work?	Source of Primary Cell Culture Tissue	AUS Protocol Number
Human	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Leukemia samples	Not applicable
Rodent	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	Mouse	2009-010
Non-human primate	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		
Other (specify)	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No		

2.3 Please indicate the type of established cells that will be grown in culture in:

Cell Type	Is this cell type used in your work?	Specific cell line(s)*	Containment Level of each cell line	Supplier / Source of cell line(s)
Human	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	See list	1, 2	ATCC
Rodent	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	See list	1	ATCC
Non-human primate	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			
Other (specify)	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			

**Please attach a Material Safety Data Sheet or equivalent from the supplier. (For more information, see www.atcc.org)*

2.4 For above named cell types(s) indicate PHAC or CFIA containment level required 1 2 2+ 3

Additional Comments: Hyperlinks to Material Safety Data Sheets are provided with the attached list.

3.0 Use of Human Source Materials

3.1 Does your work involve the use of human source materials? YES NO
 If no, please proceed to Section 4.0

3.2 Indicate in the table below the Human Source Material to be used.

Human Source Material	Source/Supplier /Company Name	Is Human Source Material Infected With An Infectious Agent? YES/UNKNOWN	Name of Infectious Agent (If applicable)	PHAC or CFIA Containment Level (Select one)
Human Blood (whole) or other Body Fluid	London Regional Cancer Centre	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> Unknown	N/A	<input type="checkbox"/> 1 <input checked="" type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
Human Blood (fraction) or other Body Fluid		<input type="checkbox"/> Yes <input type="checkbox"/> Unknown		<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
Human Organs or Tissues (unpreserved)		<input type="checkbox"/> Yes <input type="checkbox"/> Unknown		<input type="checkbox"/> 1 <input type="checkbox"/> 2 <input type="checkbox"/> 2+ <input type="checkbox"/> 3
Human Organs or Tissues (preserved)		Not Applicable		Not Applicable

Additional Comments: _____

4.0 Genetically Modified Organisms and Cell lines

4.1 Will genetic modifications be made to the microorganisms, biological agents, or cells described in Sections 1.0 and 2.0? YES NO If **NO**, please proceed to Section 5.0

4.2 Will genetic modification(s) involving plasmids be done? YES, complete table below NO

Bacteria Used for Cloning *	Plasmid(s) **	Source of Plasmid	Gene Transformed or Transfected	Will there be a change due to transformation of the bacteria?	Will there be a change in the pathogenicity of the bacteria after the genetic modification?	What are the consequences due to the transformation of the bacteria?
E. coli (cloning and subcloning strains)	See list	various - see list attached to this form.	various	no	no	none

* *Please attach a Material Safety Data Sheet or equivalent if available.*

** *Please attach a plasmid map.*

****No Material Safety Data Sheet is required for the following strains of E. coli:*

http://www.uwo.ca/humanresources/docandform/docs/ohs/CFIA_Ecoli_list.pdf

4.3 Will genetic modification(s) of bacteria and/or cells involving viral vectors be made?

YES, complete table below NO

Virus Used for Vector Construction	Vector(s) *	Source of Vector	Gene(s) Transduced	Describe the change that results from transduction
Retrovirus	MSCV/MIGR1	Clontech	Various	Various

* *Please attach a Material Safety Data Sheet or equivalent.*

4.3.1 Will virus be replication defective? YES NO

4.3.2 Will virus be infectious to humans or animals? YES NO

4.3.3 Will this be expected to increase the containment level required? YES NO

5.0 Will genetic sequences from the following be involved?

- ◆ HIV NO YES, specify
- ◆ HTLV 1 or 2 or genes from any Level 1 or Level 2 pathogens NO YES, specify
- ◆ SV 40 Large T antigen NO YES
- ◆ E1A oncogene NO YES
- ◆ Known oncogenes NO YES, specify
- ◆ Other human or animal pathogen and or their toxins NO YES, specify

5.1 Is any work being conducted with prions or prion sequences? NO YES

Additional Comments: **Retroviral Gene Transfer and Expression User Manual is attached to this form.**

6.0 Human Gene Therapy Trials

6.1 Will human clinical trials be conducted involving a biological agent? YES NO
(including but not limited to microorganisms, viruses, prions, parasites or pathogens of plant or animal origin)
If no, please proceed to Section 7.0

6.2 If YES, please specify which biological agent will be used:
Please attach a full description of the biological agent.

6.3 Will the biological agent be able to replicate in the host? YES NO

6.4 How will the biological agent be administered?

6.5 Please give the Health Care Facility where the clinical trial will be conducted:

6.6 Has human ethics approval been obtained? YES, number: NO PENDING

7.0 Animal Experiments

7.1 Will live animals be used? YES NO If **NO**, please proceed to section 8.0

7.2 Name of animal species to be used **Mouse**

7.3 AUS protocol # **2009-010**

7.4 List the location(s) for the animal experimentation and housing. **Robarts Facilities**

7.5 Will any of the agents listed in section 4.0 be used in live animals
 NO YES, specify:

7.6 Will the agent(s) be shed by the animal:
 YES NO, please justify:

8.0 Use of Animal species with Zoonotic Hazards

8.1 Will any animals with zoonotic hazards or their organs, tissues, lavages or other body fluids including blood be used (see list below)? YES NO - If **NO**, please proceed to section 9.0

8.2 Will live animals be used? YES NO

8.3 If **YES**, please specify the animal(s) used:

- | | | |
|-----------------------------|--|-----------------------------|
| ◆ Pound source dogs | <input type="checkbox"/> YES | <input type="checkbox"/> NO |
| ◆ Pound source cats | <input type="checkbox"/> YES | <input type="checkbox"/> NO |
| ◆ Cattle, sheep or goats | <input type="checkbox"/> YES, species | <input type="checkbox"/> NO |
| ◆ Non-human primates | <input type="checkbox"/> YES, species | <input type="checkbox"/> NO |
| ◆ Wild caught animals | <input type="checkbox"/> YES, species & colony # | <input type="checkbox"/> NO |
| ◆ Birds | <input type="checkbox"/> YES, species | <input type="checkbox"/> NO |
| ◆ Others (wild or domestic) | <input type="checkbox"/> YES, specify | <input type="checkbox"/> NO |

8.4 If no live animals are used, please specify the source of the specimens:

9.0 Biological Toxins and Hormones

9.1 Will toxins or hormones of biological origin be used? YES NO If **NO**, please proceed to Section 10.0

9.2 If YES, please name the toxin(s) or hormones(s)
Please attach information, such as a Material Safety Data Sheet, for the toxin(s) used.

9.3 What is the LD₅₀ (specify species) of the toxin or hormone

9.4 How much of the toxin or hormone is handled at one time*?

9.5 How much of the toxin or hormone is stored*?

9.6 Will any biological toxins or hormones be used in live animals? YES NO
If **YES**, Please provide details:

*For information on biosecurity requirements, please see:
http://www.uwo.ca/humanresources/docandform/docs/healthandsafety/biosafety/Biosecurity_Requirements.pdf

Additional Comments: _____

10.0 Insects

10.1 Do you use insects? YES NO - If **NO**, please proceed to Section 11.0

10.2 If YES, please give the name of the species.

10.3 What is the origin of the insect?

10.4 What is the life stage of the insect?

10.5 What is your intention? Initiate and maintain colony, give location:
 "One-time" use, give location:

10.6 Please describe the risk (if any) of escape and how this will be mitigated:

10.7 Do you use insects that require a permit from the CFIA permit? YES NO
If **YES**, Please attach the CFIA permit & describe any CFIA permit conditions:

11.0 Plants

- 11.1 Do you use plants? YES NO - If **NO**, please proceed to Section 12.0
- 11.2 If YES, please give the name of the species.
- 11.3 What is the origin of the plant?
- 11.4 What is the form of the plant (seed, seedling, plant, tree...)?
- 11.5 What is your intention? Grow and maintain a crop "One-time" use
- 11.6 Do you do any modifications to the plant? YES NO
If yes, please describe:
- 11.7 Please describe the risk (if any) of loss of the material from the lab and how this will be mitigated:
- 11.8 Is the CFIA permit attached? YES NO
If **YES**, Please attach the CFIA permit & describe any CFIA permit conditions:

12.0 Import Requirements

- 12.1 Will any of the above agents be imported? YES, country of origin NO
If **NO**, please proceed to Section 13.0
- 12.2 Has an Import Permit been obtained from HC for human pathogens? YES NO
- 12.3 Has an import permit been obtained from CFIA for animal or plant pathogens? YES NO
- 12.4 Has the import permit been sent to OHS? YES, please provide permit # NO

13.0 Training Requirements for Personnel Named on Form

All personnel named on the above form who will be using any of the above named agents are required to attend the following training courses given by OHS:

- ◆ Biosafety
- ◆ Laboratory and Environmental/Waste Management Safety
- ◆ WHMIS (Western or equivalent)
- ◆ Employee Health and Safety Orientation

As the Principal Investigator, I have ensured that all of the personnel named on the form who will be using any of the biological agents in Sections 1.0 to 9.0 have been trained.

An X in the check box indicates you agree with the above statement..
Enter Your Name Rodney P. DeKoter **Date:** March 6, 2012

14.0 Containment Levels

14.1 For the work described in sections 1.0 to 9.0, please indicate the highest HC or CFIA Containment Level required. 1 2 2+ 3

14.2 Has the facility been certified by OHS for this level of containment?
 YES, location and date of most recent biosafety inspection: **August 4, 2011**
 NO, please certify
 NOT REQUIRED for Level 1 containment

14.3 Please indicate permit number (not applicable for first time applicants): **BIO-UWO-0237**

15.0 Procedures to be Followed

15.1 Are additional risk reduction measures necessary beyond containment level 1, 2, 2+ or 3 measures that are unique to these agents? YES NO
If **YES** please describe:

15.2 Please outline what will be done if there is an exposure to the biological agents listed such as a needlestick injury or an accidental splash:
Staff/Student health will be contacted.

15.3 As the Principal Investigator, I will ensure that this project will follow the Western Biosafety Guidelines and Procedures Manual for Containment Level 1 & 2 Laboratories (and the Level 3 Facilities Manual for Level 3 projects). I will ensure that UWO faculty, staff and students working in my laboratory have an up-to-date Hazard Communication Form, found at <http://www.shs.uwo.ca/workplace/workplacehealth.html>

An X in the check box indicates you agree with the above statement...
Enter Your Name Rodney DeKoter Date: March 6, 2012

15.4 Additional Comments: _____

16.0 Approvals

1) UWO Biohazards Subcommittee: SIGNATURE: _____
Date: _____

2) Safety Officer for the University of Western Ontario SIGNATURE: _____
Date: _____

3) Safety Officer for Institution where experiments will take place (if not UWO):
SIGNATURE: _____
Date: _____

Approval Number: _____ Expiry Date (3 years from Approval): _____

Special Conditions of Approval:

DeKoter Laboratory Competent E. Coli Strains

<u>Strain Name</u>	<u>Company</u>	<u>MSDS Link</u>
DH5 alpha	Life Technologies	https://tools.invitrogen.com/content/sfs/msds/2010/18265017_MTR-NAIV_EN.pdf
XL1-blue	Agilent	http://www.genomics.agilent.com/files/MSDS/200236_NAEnglish.pdf
XL10-gold	Agilent	http://www.genomics.agilent.com/files/MSDS/200314_NAEnglish.pdf

List of Cell Lines in the DeKoter Lab

Name	Mouse/Human	Link to Publication or ATCC Description
HL-60	h	http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/
WEHI-279	m	http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/
WEHI-231	m	http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/
38B9	m	http://www.ncbi.nlm.nih.gov/pubmed?term=6277505
1-8 cells	m	http://www.ncbi.nlm.nih.gov/pubmed?term=6277505
EL-4	m	http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/
D1	m	http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/
MC/9	m	http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/
J774.16	m	http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/
A20	m	http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/
AA4.1 hybridoma	m	http://www.ncbi.nlm.nih.gov/pubmed/6606670
Plat-E	h	http://www.ncbi.nlm.nih.gov/pubmed/10871756
J558	m	http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/
J558-IL-7	m	http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/
S17	m	http://www.ncbi.nlm.nih.gov/pubmed/1694879
HeLa	h	http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/
WEHI-3B	m	http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/
70Z/3 pre-B cell line	m	http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/
MAM Cells (M-CSF-producing)	m	http://www.ncbi.nlm.nih.gov/pubmed/11672538
OP9 stromal cells	m	http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/
OP42 Stromal Cells	m	http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/
ST2 Stromal Cells	m	http://www.ncbi.nlm.nih.gov/pubmed?term=2891538
ST2-pac Stromal Cells	m	http://www.ncbi.nlm.nih.gov/pubmed?term=2891538
Jurkat	h	http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/
VP245 hybridoma	m	http://www.ncbi.nlm.nih.gov/pubmed?term=7875207
SL156 hybridoma	m	http://www.ncbi.nlm.nih.gov/pubmed?term=7875207
LM34 hybridoma (anti lambda5)	m	http://www.ncbi.nlm.nih.gov/pubmed?term=7875207

NIH 3T3	m	http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/
GP+E-86	m	http://www.ncbi.nlm.nih.gov/pubmed/2291567
HEK-293	h	http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/
phoenix	h	http://clontech.com
GP2 packaging cells (Clontech)	h	http://clontech.com
MEL	m	http://www.ncbi.nlm.nih.gov/pubmed/6937265
RAW264.7	m	http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/
THP-1	h	http://www.atcc.org/ATCCAdvancedCatalogSearch/ProductDetails/tabid/452/
Lines Generated in DeKoter Lab:		
IL-7-dependent B cells	m	http://www.ncbi.nlm.nih.gov/pubmed/11869689
GM-CSF-dependent myeloid cells	m	http://www.ncbi.nlm.nih.gov/pubmed/17309818
IL-3-dependent myeloid cells	m	http://www.ncbi.nlm.nih.gov/pubmed/17588474

['Default.aspx?ATCCNum=CCL-240&Template=cellBiology](#)
['Default.aspx?ATCCNum=CRL-1704&Template=cellBiology](#)
['Default.aspx?ATCCNum=CRL-1702&Template=cellBiology](#)

['Default.aspx?ATCCNum=TIB-39&Template=cellBiology](#)
['Default.aspx?ATCCNum=CRL-10915&Template=cellBiology](#)
['Default.aspx?ATCCNum=CRL-8306&Template=cellBiology](#)
['Default.aspx?ATCCNum=TIB-67&Template=cellBiology](#)
['Default.aspx?ATCCNum=TIB-208&Template=cellBiology](#)

['Default.aspx?ATCCNum=TIB-6&Template=cellBiology](#)
['Default.aspx?ATCCNum=TIB-6&Template=cellBiology](#)

['Default.aspx?ATCCNum=CCL-2&Template=cellBiology](#)
['Default.aspx?ATCCNum=TIB-68&Template=cellBiology](#)
['Default.aspx?ATCCNum=TIB-158&Template=cellBiology](#)

['Default.aspx?ATCCNum=CRL-2749&Template=cellBiology](#)
['Default.aspx?ATCCNum=CRL-2749&Template=cellBiology](#)

['Default.aspx?ATCCNum=TIB-152&Template=cellBiology](#)

[Default.aspx?ATCCNum=CRL-1658&Template=cellBiology](#)

[Default.aspx?ATCCNum=CRL-1573&Template=cellBiology](#)

[Default.aspx?ATCCNum=TIB-71&Template=cellBiology](#)

[Default.aspx?ATCCNum=TIB-202&Template=cellBiology](#)

DeKoter Lab Plasmids

Note: Parent plasmids, not variants, are listed

<u>Plasmid</u>	<u>Annotation</u>	<u>MSDS or Publication Hyperlink</u>
Box 1 - Retrovirus / PU.1		
pBABE	MMLV-based retroviral vector	http://www.cellbiolabs.com/sites/default/files/MSDS%20%28RTV-xxx%29_125.pdf
MSCV/MIGR1	Murine stem cell virus based retroviral	http://www.clontech.com/CA/Products/Viral_Transduction/Retroviral_Vector_Systems/MSCV?site=10020.22372:US
pBluescript	Cloning vector - Agilent	http://www.chem.agilent.com/Library/msds/212250_NAEnglish.pdf
pCDNA3	Cloning/Expression vector - Life Techn	https://tools.invitrogen.com/content/sfs/msds/2010/350489_MTR-NAIV_EN.pdf
pGEM	Cloning vector - Promega	http://www.promega.com/~media/files/resources/msds/p2000/p2251_ashx?la=en
pCR2.1	Cloning vector - Life Technologies	http://tools.invitrogen.com/content/sfs/msds/2003/460245.pdf?CFID=12343435&CFTOKEN=7cc9285efad7d243-E8523712-F9A6-FAF7-1918E5DOCE892591
LXSN	MMLV-based retroviral vector	http://www.biomol.de/datenblaetter/imgenex/10040K.pdf
pSCA	Cloning vector - Agilent	http://www.chem-agilent.com/pdf/strata/240205.pdf
pCR4-topo	Cloning vector - Life Technologies	http://tools.invitrogen.com/content/sfs/msds/2003/460245.pdf?CFID=12343435&CFTOKEN=7cc9285efad7d243-E8523712-F9A6-FAF7-1918E5DOCE892591
pUC19	Cloning vector - New England Biolabs	http://www.neb.com/nebecomm/MSDSFiles/msdsN3041.pdf
pCITE-2(a)+	Cloning/expression vector - EMD	http://www.emdchemicals.com/life-science-research/vector-table-novagen-pcite-vector-table/c_nxmb.s10mM4AAAEh4d8Ldcaa
pGL3	Reporter vector - Promega	http://www.promega.com/resources/msds/msds/e1000/e1751/
pGL2	Reporter vector - Promega	http://www.promega.com/resources/msds/msds/e1000/e1641/

Retroviral Gene Transfer and Expression User Manual



Clontech

United States/Canada
800.662.2566

Asia Pacific
+1.650.919.7300

Europe
+33.(0)1.3904.6880

Japan
+81.(0)77543.6116

Clontech Laboratories, Inc.
A Takara Bio Company
1290 Terra Bella Ave.
Mountain View, CA 94043
Technical Support (US)
E-mail: tech@clontech.com
www.clontech.com

PT3132-1 (PR993327)
Published 29 January 2010

Table of Contents

I. Introduction	4
II. List of Components	12
III. Additional Materials Required	14
IV. Safety & Handling of Retroviruses	15
V. Plasmid Manipulations	16
A. Propagating Plasmids	16
B. Generating Expression Vectors	16
VI. Culturing Packaging Cell Lines	17
A. General Considerations	17
B. Starting Cells from Frozen Stocks	17
C. Maintaining Packaging Cell Lines	18
D. Freezing Packaging Cell Lines	18
VII. Virus Production	19
A. Transfecting Retroviral Vectors	20
B. Selecting Stable Virus-Producing Cell Lines	22
C. Concentrating Virus	22
D. Producing Virus from Stable Packaging Cell Clone (PT67)	22
E. Storage of Viral Stocks	23
VIII. Determining Viral Titer	24
A. General Considerations	24
B. Procedure for Determining Viral Titer	24
C. Alternative Methods	25
IX. Infecting Target Cells	26
A. General Considerations	26
B. Infecting Target Cells	26
X. Troubleshooting Guide	28
XI. References	31
Appendix A: Culture Plate Conversions	34
Appendix B: Titration of Antibiotic Stocks (Kill Curves)	35
Appendix C: Additional Viral Infection Methods	36

Table of Contents continued

List of Figures

Figure 1.	Virus production in packaging cell lines	5
Figure 2.	Overview of transient and stable virus production	6
Figure 3.	Overview of infectious retrovirus production	19

List of Tables

Table I:	Host range of packaging cell lines expressing different envelopes	7
Table II:	Packaging cell lines to use for infection	8
Table III:	Culture plate conversions	34

Note: The viral supernatants produced by these retroviral systems could, depending on your DNA insert, contain potentially hazardous recombinant virus. Due caution must be exercised in the production and handling of recombinant retrovirus. **The user is strongly advised not to create retroviruses capable of expressing known oncogenes in amphotropic or polytropic host range viruses.**

Please refer to the appropriate regional and institutional guidelines on handling retroviruses. Please contact your on-site safety officer for specific requirements in your facility. In the United States, NIH guidelines require that retroviral production and transduction be performed in a Biosafety Level 2 facility. For more information, see appropriate HHS publications. Section IV in this User Manual contains a brief description of Biosafety Level 2 as well as other general information and precautions. <http://bmbi.od.nih.gov> and www.niehs.nih.gov/odhsb/biosafe/nih/rdna-apr98.pdf

I. Introduction

Retroviral gene transfer is a technique for efficiently introducing stable, heritable genetic material into the genome of any dividing cell type (Ausubel *et al.*, 1995; Coffin *et al.*, 1996). This User Manual supports many Clontech packaging cell lines, retroviral vectors, and retroviral expression systems.

Retroviral Gene Transfer Technology

Current retroviral gene transfer technology is based on the coordinated design of packaging cell lines and retroviral expression vectors. The development of packaging lines—cell lines that package recombinant retroviral RNAs into infectious, replication-incompetent particles—created a new level of safety and control (Figure 1; Mann *et al.*, 1983; Miller & Buttimore, 1986). To develop a packaging cell line, the viral gag, pol, and env genes—necessary for particle formation and replication—are stably integrated into the genome of the packaging cell line. The separate introduction and integration of the structural genes minimizes the chances of producing replication-competent virus due to recombination events during cell proliferation (Morgenstern & Land, 1990; Miller & Chen, 1996). Retroviral expression vectors provide the packaging signal Ψ^+ , transcription and processing elements, and a target gene. Inserts of up to 6.5 kb can be efficiently packaged. Transfection of the retroviral vector into a packaging cell line produces high-titer, replication-incompetent virus.

The viral env gene, expressed by the packaging cell line, encodes the envelope protein, which determines the range of infectivity (tropism) of the packaged virus. Viral envelopes are classified according to the receptors used to enter host cells. For example, ecotropic virus can recognize a receptor found on only mouse and rat cells. Amphotropic virus recognizes a receptor found on a broad range of mammalian cell types. Dualtropic virus recognizes two different receptors found on a broad range of mammalian cell types.

A pantropic packaging cell line provided a major advancement in retroviral gene transfer, as this cell line produces virus that can infect both mammalian and non-mammalian cells (Burns *et al.*, 1993). Using this cell line, virions are pseudo-typed with the envelope glycoprotein from the vesicular stomatitis virus (VSV-G). Unlike other viral envelope proteins, VSV-G mediates viral entry through lipid binding and plasma membrane fusion (Emi *et al.*, 1991). Stable expression of the VSV-G envelope protein is toxic; thus, the packaging cell line only contains the viral gag and pol genes. Virus is produced by transiently cotransfecting a retroviral expression vector and pVSV-G into a pantropic packaging cell line.

Once a packaging cell line is transfected with a retroviral expression vector that contains a packaging signal, the viral genomic transcript containing the target gene and selectable marker are packaged into infectious virus within 48–72 hrs. Alternatively, you can use antibiotic selection to select cells that stably express the integrated vector. Stable virus-producing cells can be frozen and used in later experiments. Virus produced by both transient and stable

I. Introduction *continued*




Figure 1. Virus production in packaging cell lines. The *gag*, *pol* and *env* genes required for viral production are integrated into the packaging cells genome. The vector provides the viral packaging signal, commonly denoted Ψ^+ , a target gene, and drug-resistance marker.


transfections can infect target cells and transmit target genes; however, it cannot replicate within target cells because the viral structural genes are absent.

The Retro-X™ Universal Packaging System (Cat. No. 631530) is a transient packaging system that allows you to select the envelope according to the tropism needed for your experiments. It includes the GP2-293 cell line, which has the viral *gag* and *pol* genes incorporated in its genome. The remaining portion of the packaging function, the viral *env* gene, must be cotransfected with the retroviral expression vector bearing the gene of interest. The kit includes vectors that encode ecotropic, amphotropic, dualtropic (10A1) and pantropic (VSV-G) envelope proteins. This allows you to cater the tropism or host range of the packaged virus to your needs by determining which envelope protein is used.

I. Introduction *continued*


Transient Production

Plate packaging cells



Target Cell Infection

Plate target cells



Stable Production

Plate packaging cells




Figure 2. Overview of transient and stable virus production. To produce high-titer virus transiently, transfect a retroviral expression vector into an HEK 293-based packaging cell line. After 48–72 hours, collect virus and determine the viral titer or infect a target cell line. Alternatively, you can use antibiotic selection to develop clones that stably produce high-titer retrovirus.

In addition, Clontech offers a variety of stable packaging cell lines. Table II provides a detailed overview of each cell line.

• RetroPack™ PT67 Cell Line

The RetroPack PT67 Cell Line (Cat. No. 631510) is derived from a mouse fibroblast (NIH 3T3) cell line designed for stably producing high-titer retrovirus. RetroPack PT67 cells package virus with a dualtropic (or polytropic) envelope, 10A1, that recognizes receptors on mouse, rat, human, hamster, mink, cat, dog, and monkey cells. Virus produced by these cells can enter target cells via two surface molecules, the amphotropic retrovirus receptor, RAM1 (Pit2), and the GALV (Pit1) receptor. Two viral receptors means that if one receptor is not abundantly expressed by a given spe-

I. Introduction *continued*

TABLE I: HOST RANGE OF PACKAGING CELL LINES EXPRESSING DIFFERENT ENVELOPES

Target Cells ^b	Envelopes ^a			
	Dualtropic	Amphotropic	Ecotropic	Pantropic ^c
Mouse	+	+	+	+
Rat	+	+	+	+
Hamster	+	+/-	-	+
Mink	+	+	-	+
Cat	+	+	-	+
Dog	+	+	-	+
Monkey	+	+	-	+
Human	+	+	-	+
Avian	-	-	-	+
Fish	-	-	-	+
Insect	-	-	-	+

^aSee Table II: Packaging Cell Lines for a description of the envelope proteins.

^bThis listing of the most common target cells is not intended to be exclusive. Other cells which are not listed may also be infected.

^cVirus packaged with the pantropic envelope also infects molusk, amphibian, ameoba and nematode cells.

cies or cell type, the alternate receptor may still allow viral entry. Thus, virus packaged by RetroPack PT67 has a broad mammalian host range (Table I; Miller & Miller, 1994; Miller, 1996). These cells are best suited for stable virus production.

• **EcoPack2™-293 Cell Line**

The EcoPack2-293 Packaging Cell Line (Cat. No. 631507) is a human embryonic kidney, HEK 293-derived cell line designed for rapid, transient production of high-titer, ecotropic retrovirus (Figure 2). EcoPack2-293 cells can also be used to produce retrovirus stably. Bleomycin- and hygromycin-resistance genes were used to separately introduce the viral gag-pol and env genes. Virus produced by EcoPack2-293 cells possess an ecotropic envelope (gap70), and thus can infect both mouse and rat cells (Table I). Retroviral sequence within the cell genome has been minimized, reducing the likelihood that replication-competent virus will be produced through recombination. EcoPack2-293 cells are more adherent and produce higher viral titers in comparison to our original EcoPack™-293 cells.

• **AmphoPack™-293 Cell Line**

The AmphoPack-293 Packaging Cell Line (Cat. No. 631505) is a human embryonic kidney, HEK 293-derived cell line designed for rapid, transient

I. Introduction *continued*

TABLE II: PACKAGING CELL LINES

	Retropack™ PT67	EcoPack2™ -293	AmphoPack™ -293	GP2-293
Cell type	NIH 3T3	HEK 293	HEK 293	HEK 293
Tropism	Dualtropic	Ecotropic	Amphotropic	Pantropic ^a Env-specific ^b
Target cells	Broad mammalian	Murine, rat	Broad mammalian	Mammalian, or non-mammalian
Envelope	10A1	gap70	4070A	VSV-G ^a Env-specific ^b
Receptors	GALV (Pit1), RAM1 (Pit2)	mCAT-1	RAM1	phosphatidylserine, phosphatidyl-inositol, & G _{MS} ganglioside ^a
Markers^c gag-pol env	TK DHFR	Bleo Hyg	Bleo Puro	DHFR –

production of high-titer, amphotropic retrovirus (Figure 2). AmphoPack-293 cells can also be used to produce high-titer retrovirus stably. Bleomycin- and puromycin-resistance genes were used to separately introduce the viral gag-pol and env genes. Therefore, the popular neomycin and hygromycin selection markers can be used to develop clones that stably produce high-titer virus. Virus produced by AmphoPack-293 cells express an amphotropic envelope (4070A), and thus can infect a broad range of mammalian cell types (Table I).

- **GP2-293 Packaging Cell Line**

The Pantropic Retroviral Expression System (Cat. No. 631512) features GP2-293, a HEK 293-based packaging cell line that stably expresses the viral gag and pol genes. To produce infectious virus, cotransfect GP2-293 with a retroviral expression vector and pVSV-G, a plasmid that expresses VSV-G from the CMV promoter (Yee *et al.*, 1994). The VSV-G envelope must be cotransfected with the vector due to toxicity caused by the fusogenic properties of the VSV-G protein. A positive control cell line, GP2-293 Luc, allows verification that pVSV-G is functioning properly and that target cells can be infected. This system takes advantage of the envelopes ability to infect non-mammalian cells (Table I).

The Retro-X™ Universal Expression System (Cat. No. 631530) also features the GP2-293 cell line. To produce infectious virus, cotransfect GP2-293 with a retroviral expression vector and the vector that encodes

I. Introduction *continued*

the envelope of your choice: pAmpho, pEco, p10A1, or pVSV-G. A positive control vector, pQCLIN, allows verification that the envelope vector is functioning properly and that target cells can be infected. The major advantages of the Universal Packaging System are as follows:

- The system can be used with any MMLV-based vector.
- The tropism can be changed to accommodate the desired cell type.
- High titers are generated (10^6 – 10^7).
- Infectious virus can be obtained in 48 hours, and the packaging system is therefore ideal for testing multiple constructs.
- Excess Gag and Pol proteins are not generated, which may be detrimental (Yap *et al.*, 2000).

Retroviral Expression Vectors

Clontech offers a wide range of retroviral expression vectors that can all be used with our various packaging cell lines. For more detailed descriptions of our vectors and sequence information, visit our www.clontech.com and navigate to the vector information page. All vectors contain the extended retroviral packaging signal, Ψ^+ , which promotes high-titer virus production. With the exception of the expression vectors in the MSCV Retroviral Expression System (Cat. No. 634401), all vectors are derived from Moloney murine leukemia virus (MMLV). Each vector contains a different antibiotic resistance marker—neomycin, hygromycin, or puromycin—allowing you to choose the cloning vector appropriate for the desired selection method.

The MSCV Vectors contain a specifically designed long terminal repeat (LTR) from the murine stem cell PCMV virus. PCMV stands for PCC4-cell-passaged myeloproliferative sarcoma virus (Hilberg *et al.*, 1987, Hawley *et al.*, 1994). This LTR differs from the MMLV LTR by several point mutations and a deletion. These changes enhance transcriptional activation and decrease transcriptional suppression in embryonic stem and embryonal carcinoma cells. As a result, the LTR drives high-level constitutive expression of a target gene in stem cells and other mammalian cell lines (Hawley *et al.*, 1994).

The Retro-X™ Q Vectors are self-inactivating bicistronic expression vectors designed to express a target gene along with an antibiotic selection marker without the risk of promoter interference from the 5' LTR. In the case of pQCXIX two target genes may be expressed. Upon transfection into a packaging cell line, Q Vectors can transiently express, or integrate and stably express a viral genomic transcript containing the CMV immediate early promoter, gene-of-interest, IRES and antibiotic selection marker. Also included in the viral genomic transcript are the necessary viral RNA processing elements including the LTRs, packaging signal (Ψ^+), and tRNA primer binding site. The self-inactivating feature of the vectors is provided by a deletion in the 3' LTR enhancer region (U3). During reverse transcription

I. Introduction *continued*

of the retroviral transcript in the infected cell, the inactivated 3' LTR is copied and replaces the 5' LTR, resulting in inactivation of the 5' LTR promoter (CMV). The gene of interest and antibiotic resistance gene are expressed from an internal CMV promoter and co-translated, via the internal ribosome entry site (IRES), as a bicistronic message in mammalian cells (Jackson *et al.*, 1990; Jang *et al.*, 1988).

Retroviral Delivery of RNAi Constructs

Our pSIREN-Retro-Q Vector is designed for gene silencing experiments based on the RNA interference phenomenon (July 2003 Clontechiques). Expression of silencing RNAs (shRNA) can decrease expression of a target gene in vivo (Xia *et al.*, 2002). For more information about gene silencing technology, and use of the pSIREN vectors, please refer to the Knockout RNAi Systems User Manual (PT3739-1). Viral delivery of shRNAs has the following advantages:

1. Retroviral expression systems are capable of highly efficient gene delivery.
 - Viral vectors take advantage of viral mechanisms that allow efficient delivery of their nucleic acids to susceptible cell targets. Since recombinant viruses can infect nearly 100% of a cell population, the selection process used to enrich the population for a construct can be eliminated. If less than 100% of cells carry the construct, expression of specified gene may still be detected.
 - This efficiency is difficult to achieve in primary cells with transfection.
 - Retroviruses integrate into the host cell's genome promoting permanent and stable gene transfer as well as persistent expression of the shRNA cassette.
 - Viral infection provides consistent, reproducible transfer of the sequence of interest. However, transfection efficiency can be low and inconsistent.
2. Copy number can be controlled with retroviral vectors. The shRNA dosage is important in maintaining gene silencing (Barton & Medzhitov, 2002).
3. Retroviral vector-based shRNAs produced within a retroviral packaging cell do not affect the titer or production of virus particles (Brummelkamp *et al.*, 2002).
4. Because shRNA molecules anneal to specific sequences, developing vectors that target specific cell types is unnecessary because only those cells that express the targeted sequence will be affected by the vector.
5. Retroviral shRNA expression is more economical than chemical synthesis of small RNA, which is expensive for labs to do on a continuous basis.
6. Retroviral-vector based shRNA expression provides the option for stable expression.

I. Introduction *continued*

Adeno-X™ Adenoviral Gene Expression

For experiments requiring transient gene expression in non-dividing or difficult-to-transfect cells, we recommend our Adeno-X™ Expression Systems. These adenovirus-based systems enable high-level protein expression in a wide variety of cell types (dividing or non-dividing) without the need for plaque purification (January 2000 & April 2003 Clontechiques).

II. List of Components

Store cell lines in liquid nitrogen (-196°C). Store all plasmids and primers at -20°C .

Retro-X™ System (Cat. No. 631508)

- 1 ml RetroPack PT67 Cell Line (2×10^6 cells/ml)
- 40 μl pLNCX2 Retroviral Vector (0.5 $\mu\text{g}/\mu\text{l}$)
- 40 μl pLXSN Retroviral Vector (0.5 $\mu\text{g}/\mu\text{l}$)
- 40 μl pLAPSN Retroviral Vector (0.5 $\mu\text{g}/\mu\text{l}$)
- 100 μl pLNCX Seq/PCR Primer (20 μM)
- 100 μl pLXSN Seq/PCR Primer (20 μM)

Retro-X™ Q Vector Set (Cat. No. 631516)

- 20 μg pQCXIN Retroviral Vector (500 ng/ μl)
- 20 μg pQCXIH Retroviral Vector (500 ng/ μl)
- 20 μg pQCXIP Retroviral Vector (500 ng/ μl)
- 20 μg pQCLIN Retroviral Vector (500 ng/ μl)
- 100 μl 5' pQC Seq/PCR Primer (20 μM)
- 100 μl 3' pQC Seq/PCR Primer (20 μM)

LRXC Retroviral Vector Set (Cat. No. 631511)

- 20 μg pLNCX2 Retroviral Vector (0.5 $\mu\text{g}/\mu\text{l}$)
- 20 μg pLHCX Retroviral Vector (0.5 $\mu\text{g}/\mu\text{l}$)
- 20 μg pLPCX Retroviral Vector (0.5 $\mu\text{g}/\mu\text{l}$)
- 100 μl 5' pLNCX Seq/PCR Primer (20 μM)
- 100 μl 3' pLNCX Seq/PCR Primer (20 μM)

MSCV Retroviral Expression System (Cat. No. 634401)

- 1 ml RetroPack PT67 Cell Line (2×10^6 cells/ml)
- 20 μg pMSCVneo Retroviral Vector (0.5 $\mu\text{g}/\mu\text{l}$)
- 20 μg pMSCVhyg Retroviral Vector (0.5 $\mu\text{g}/\mu\text{l}$)
- 20 μg pMSCVpuro Retroviral Vector (0.5 $\mu\text{g}/\mu\text{l}$)
- 100 μl 5' pMSCV Primer (20 μM)
- 100 μl 3' pMSCV Primer (20 μM)

Pantropic Retroviral Expression System (Cat. No. 631512)

- 1 ml GP2-293 Packaging Cell Line (2×10^6 cells/ml)
- 20 μg pLNHX Vector (0.5 $\mu\text{g}/\mu\text{l}$)
- 20 μg pLXRN Vector (0.5 $\mu\text{g}/\mu\text{l}$)
- 20 μg pLLRN Control Vector (0.5 $\mu\text{g}/\mu\text{l}$)
- 20 μg pVSV-G Vector (0.5 $\mu\text{g}/\mu\text{l}$)

II. List of Components *continued*

Retro-X™ Universal Packaging System (Cat. No. 631530)

- 1 ml GP2-293 Packaging Cell Line (2×10^6 cells/ml)
- 20 µg p10A1 Vector (0.5 µg/µl)
- 20 µg pAmpho Vector (0.5 µg/µl)
- 20 µg pEco Vector (0.5 µg/µl)
- 20 µg pVSV-G Vector (0.5 µg/µl)
- 20 µg pQCLIN Control Vector (0.5 µg/µl)

RetroPack™ PT67 Cell Line (Cat. No. 631510)

- 1 ml RetroPack PT67 Cell Line (2×10^6 cells/ml)

EcoPack2™-293 Cell Line (Cat. No. 631507)

- 1 ml EcoPack2-293 Cell Line (2×10^6 cells/ml)

AmphoPack™-293 Cell Line (Cat. No. 631505)

- 1 ml AmphoPack-293 Cell Line (2×10^6 cells/ml)

III. Additional Materials Required

- **Dulbecco's Modified Eagle's Medium** (high glucose with sodium pyruvate & glutamine; Sigma Cat. No. D5796)
- **Fetal bovine serum (FBS)**. **Note:** serum need not be heat inactivated.
- **200 mM L-Glutamine** (Sigma Cat. No. G7513)
- Solution of 10,000 units/ml **Penicillin G sodium** and 10,000 µg/ml **Streptomycin sulfate** (Sigma Cat. No. P0781)
- **Complete Medium**
Dulbecco's Modified Eagle's Medium DMEM [or Minimum Essential Medium, α Modification (α -MEM)] supplemented with 100 units/ml penicillin G sodium, 100 µg/ml streptomycin, 4 mM L-glutamine, 1 mM sodium pyruvate and 10% fetal bovine serum (FBS).
- **G418** (Cat. No. 631307)
Note: Make a 10 mg/ml active stock solution by dissolving 1 g of powder in approximately 70 ml of complete medium without supplements. Filter sterilize and store at 4°C. G418 can also be purchased as a premade solution.
- **Hygromycin** (Cat. No. 631309)
- **Puromycin** (Cat. No. 631305)
- **Polybrene** (Hexadimethrine Bromide; Sigma Cat. No. H9268)
- **Trypsin-EDTA** (Trypsin; Sigma Cat. No. T3924)
- **TNE** (50 mM Tris-HCl [pH 7.8], 130 mM NaCl, 1 mM EDTA)
- **Dulbecco's phosphate buffered saline** (DPBS; VWR Cat. No. 82020-066)
- **Cell Freezing Medium** (Sigma Cat. No. C6164) or **DMSO** (Sigma Cat. No. D2650)
- **Tissue culture plates and flasks**
- **BD Biocoat Collagen Type I 12-well plates** (BD Biosciences Cat. Nos. 354500 & 356500)
- **Cloning cylinders** (PGC Scientific Cat. No. 62-6150-40, -45)
- **NIH-3T3 cells** (ATCC Cat. No. CRL-1658)
- **CalPhos™ Mammalian Transfection Kit** (Cat. No. 631312)
- **CLONfectin™ Transfection Reagent** (Cat. No. 631301)
- **Chloroquine** (Sigma Cat. No. C6628)

IV. Safety & Handling of Retroviruses

The protocols in this User Manual require producing, handling, and storing infectious retrovirus. A thorough understanding of safe laboratory practices and potential retroviral hazards is essential.

MMLV does not naturally infect human cells; however, viruses packaged from the MMLV-based vectors described here are capable of infecting human cells if packaged in a cell line with the proper tropism. This statement is also true for PCMV-based vectors. The viral supernatants produced by these retroviral systems could, depending on your retroviral insert, contain potentially hazardous recombinant virus.

For these reasons, exercise due caution when producing and handling recombinant retrovirus. **The user is strongly advised not to create retroviruses capable of expressing known oncogenes in amphotropic, dualtropic or pantropic packaging cell lines.**

Appropriate NIH, regional, and institutional guidelines apply, as well as specific guidelines for other countries. Please contact your on-site safety officer for specific requirements in your facility. In the United States, NIH guidelines require that retroviral production and transduction be performed in a Biosafety Level 2 (BL2) facility. A brief description of BL2 is given below. It is neither detailed nor complete. More information about BL2 guidelines is available at <http://bmbi.od.nih.gov/contents.htm> and more information about the risk group assessment for our viral systems is available at <http://www4.od.nih.gov/oba/rac/guidelines/guidelines.html>. If possible, observe and learn the practices described below from someone who has experience working with retroviruses. For more information, see the following reference:

- Biosafety in Microbiological and Biomedical Laboratories, Fourth Edition (May 1999) HHS Pub. No. (CDC) 93-8395. U.S. Department of Health and Human Services, PHS, CDC, NIH.

Practices

- Perform work in a limited access area
- Post biohazard warning signs
- Minimize production of aerosols
- Decontaminate potentially infectious wastes before disposal
- Take precautions with sharps

Safety equipment

- Use a laminar flow hood with a HEPA filter
- Wear protective laboratory coat, face protection, and double gloves

Facilities

- Autoclave for decontamination of solid and liquid waste
- Use unrecirculated exhaust air
- Stock chemical disinfectants for spills

V. Plasmid Manipulations

A. Propagating Plasmids

1. To ensure that you have a renewable source of DNA, transform each plasmid into a suitable *E. coli* host strain (e.g., DH5 α).
2. Purify plasmids with a NucleoBond® or NucleoSpin® Plasmid Kit. Alternatively, isolate plasmids by banding on a CsCl gradient (Sambrook & Russell, 2001).

B. Generating Expression Vectors

Use standard molecular biology techniques to transfer your target gene into an expression vector (Sambrook & Russell, 2001).

1. Purify your gene fragment by any standard method. The cDNA or gene fragment must contain an ATG initiation codon. Adding a Kozak consensus ribosome binding site may improve expression levels in mammalian systems (Kozak, 1987). Please note that all sequences placed into a retroviral vector must be compatible with the retroviral life cycle and allow complete transcription of the full-length viral genome. Sequences such as poly-A signals must **not** be included (Coffin *et al.*, 1996).

You can generate the fragment using compatible restriction sites that are on either side of the gene and in the cloning vector. If no such sites are present, use PCR to incorporate suitable restriction sites into your gene fragment. PCR fragments can be conveniently cloned into any vector using our In-Fusion™ PCR Cloning Kits.

2. Digest the vector with the appropriate restriction enzyme(s), treat with phosphatase, and purify.
3. Ligate the digested vector and the target gene fragment.
4. Transform ligation mixture into *E. coli*.
5. Identify the desired recombinant plasmid by restriction analysis, and confirm orientation and junctions by sequencing.

VI. Culturing Packaging Cell Lines

A. General Considerations

The protocols in this section are intended for use with packaging cell lines from Clontech.

- The RetroPack PT67 cell line has a very short doubling time (<16 hr). Split the culture before it becomes confluent.
- The doubling time for EcoPack2-293, AmphoPack-293, and GP2-293 cell lines is 24–36 hr.
- If you experience low packaging cell line viability, grow the cells for a longer period of time to allow for cell recovery and expansion.
- All our packaging cell lines should be grown at 37°C in a humidified chamber with 5–10% CO₂. See the Certificate of Analysis for details particular to each cell line.

B. Starting Cultures from Frozen Stocks

The protocols in this User Manual provide only general guidelines for mammalian cell culture techniques. Perform all steps involving cell culture using sterile technique in a suitable hood. For those requiring more information on mammalian cell culture, we recommend the following general references:

- Culture of Animal Cells, Fourth Edition, ed. by R. I. Freshney (2000, Wiley-Liss)
- Current Protocols in Molecular Biology, ed. by F. M. Ausubel *et al.* (1995, Wiley & Sons)

Note: Frozen cells should be cultured immediately upon receipt or as soon thereafter as possible. Increased loss of viability may occur after shipping if culturing is delayed.

1. Transfer the vial of frozen cells from liquid N₂ to a 37°C water bath until just thawed. To prevent osmotic shock and to maximize cell survival, perform the following:
 - a. Rinse the outside of the tube with 70% ethanol.
 - b. Add 1 ml complete medium (prewarmed to 37°C) to tube. Transfer mixture to a 15-ml tube.
 - c. Add 5 ml complete medium and mix gently. Repeat. The final volume should be 12 ml.
 - d. Centrifuge at 250 x g for 10 min.
 - e. Remove supernatant.
2. Gently resuspend cells in 10 ml complete medium: DMEM [or Minimum Essential Medium, α Modification (α -MEM)] supplemented with 100 units/ml penicillin G sodium, 100 μ g/ml streptomycin, 4 mM L-glutamine, 1 mM sodium pyruvate and 10% fetal bovine serum.
3. Incubate cells at 37°C with 5% CO₂.

VI. Culturing Packaging Cell Lines *continued*

C. Maintaining Packaging Cell Lines

Generally, cells should be plated at 10^6 per 100-mm plate and split every 2–3 days when they reach 70–80% confluency.

Note: Plate HEK 293-based packaging cell lines on collagen-coated plates initially to promote adherence after thawing. These cells may be cultured on non-coated plates/flasks after recovery; however, if adherence is poor, we recommend collagen-coated vessels for all culturing purposes including viral packaging.

Split the cells as follows:

1. Remove medium, and wash cells once with room-temperature PBS.
Note: If cells are over-confluent, omit the wash since the cells may detach from the plate.
2. Treat with 2 ml of trypsin-EDTA solution for 0.5–1 min. Depending on the cell line, you may need to treat the cells longer.
3. Add 3 ml of media + serum to inhibit trypsinization.
4. Resuspend cells gently by pipetting.
5. Add a predetermined portion of cells to a 100-mm plate in 10 ml of complete medium. Rock the plate to distribute the cells evenly.
Note: Split RetroPack PT67 cells at a ratio of up to 1:20, and split HEK 293-based cells at a ratio of 1:10.
6. If cell viability is low, grow cells for a longer period of time, maintain higher cell densities, and verify culture conditions.

D. Freezing Packaging Cell Lines

Once a stable cell culture is established, we recommend that several aliquots of cells be frozen for future use. Prepare frozen aliquots of the packaging cells to ensure a renewable source as follows:

1. Expand the cell line into the desired number of flasks or plates.
2. When the desired number of flasks/plates reaches ~80% confluency, wash the cells once with PBS or HBSS, trypsinize using standard tissue-culture procedures (Freshney, 2000), add 2–4 volumes of complete medium to neutralize trypsin, and harvest cells.
3. Count the cells using a hemocytometer (Freshney, 2000), and collect by centrifugation ($250 \times g$ for 10 min at room temperature).
4. Resuspend in 4°C cell freezing medium containing 10% DMSO at $1\text{--}2 \times 10^6$ cells/ml.
5. Dispense 1-ml aliquots into labeled freezing vials and place in a cell freezing container (reduces temperature $\sim 1^\circ\text{C}/\text{min}$) at -80°C overnight. Alternatively, place the vials on ice or at -20°C for 1–2 hr, transfer to an insulated container such as a foam ice chest, and place in a -80°C freezer for several hours to overnight.
6. Transfer vials to liquid nitrogen.
7. Two or more weeks later. To confirm viability of frozen stocks, start a fresh culture of each frozen cell type, as described in Section B above.

VII. Virus Production

This section provides detailed procedures for virus production, target cell infection, and stable clone selection. For more detailed information or related protocols, see Coffin & Varmus (1996) or Ausubel et al. (1995). Figure 3 provides an overview of methods for producing high-titer virus using RetroPack PT67, EcoPack2-293, Amphopack-293, and GP2-293 cells.

Transient Virus Production

Stable Virus Production

RetroPack™ PT67

1. Transfect with retroviral vector.
2. Select stable clones.
3. Determine viral titer.
4. Infect target cells.

EcoPack2™-293 & AmphoPack™-293

- | | | |
|---|----|--|
| <ol style="list-style-type: none"> 1. Transfect with retroviral vector 2. Determine viral titer. 3. Infect target cells. | or | <ol style="list-style-type: none"> 2. Select stable clones. 3. Determine viral titer. 4. Infect target cells. |
|---|----|--|

GP2-293

- | | | |
|--|----|---|
| <ol style="list-style-type: none"> 1. Cotransfect with retroviral vector & envelope vector (pVSV-G, pEco, pAmpho, or p10A1). 2. Determine viral titer. 3. Concentrate virus (optional, for VSV-G) 4. Infect target cells | or | <ol style="list-style-type: none"> 1. Transfect with retroviral vector (omit envelope vector). 2. Select stable clones. 3. Before each infection, transiently transfect with envelope vector. 4. Concentrate virus (optional) 5. Determine viral titer 6. Infect target cells |
|--|----|---|

Figure 3. Overview of infectious retrovirus production.

VII. Virus Production *continued*

A. Transfecting Retroviral Vectors

Transfect by any standard method. We routinely use 60-mm plates for culturing packaging cell lines; See Additional Materials Required. Typically, transfections are done in smaller volumes than culturing.

For maximal transfection efficiencies, we recommend the CalPhos™ Mammalian Transfection Kit (Cat. No. 631312). For maximal transfection efficiency in liposome-mediated transfections, we recommend Clonfectin™ Transfection Reagent (Cat. No. 631301). To optimize your transfection protocol, you can transfect the host cell line with a non-inducible reporter expression vector, such as our pLAPSN included in our Retro-X™ System (Cat. No. 631508), or Living Colors™ Vectors, and assay for reporter gene activity.

After choosing a method of transfection, optimize cell density (usually 60–80% confluency or $1-2 \times 10^6$ cells/60 mm plate), the amount and purity of the DNA, media conditions, and transfection time. If a transfection method is already established in your laboratory, proceed with those conditions. Keep optimized parameters constant to obtain reproducible results.

1. Clone your target gene into a retroviral expression vector, or use the provided control vector for control experiments.

Note: Use only high quality plasmid DNA. We recommend using a NucleoBond or NucleoSpin Plasmid Kit.

2. 12–24 hr before transfection, plate packaging cells on a 60-mm plate at 60–80% confluency ($1-2 \times 10^6$ cells/60-mm plate).

Note: Adding 25 μ M chloroquine just prior to transfection may increase transfection efficiency 2–3 fold. Prepare a 25 mM stock of chloroquine in distilled water and filter sterilize. 1–2 hr before transfection, replace medium with medium containing chloroquine (Pear et al., 1993).

3. Transfect each 60-mm plate with the following amount of plasmid DNA:

For RetroPack™ PT67, EcoPack™ 2-293 & AmphoPack™ -293:
~5–10 μ g of plasmid DNA

For GP2-293: ~5 μ g of expression vector and ~5 μ g envelope vector

Notes:

- When using GP2-293 cells, envelope vector must be cotransfected.
- When using a CaPO₄-based transfection method, **the final volume of transfection mixture should not exceed 0.5 ml for a 60-mm plate or 1 ml for a 100-mm plate.** More than 1 ml of CaPO₄ precipitants can be toxic to cells. Add the transfection solution to the medium and evenly distribute the solution on the cells. If toxicity is observed, perform transfection with 0.5 ml of the transfection mix.
- 6–8 hr after transfection, you may perform glycerol shock treatment to increase the uptake of DNA (Freshney, 2000).

VII. Virus Production *continued*

4. For RetroPack PT67 cells, aspirate culture medium 10–24 hr after transfection. Wash RetroPack PT67 cells twice with PBS, and add 3 ml of complete medium. Proceed to Section VII.B.
5. For HEK 293-based cell lines, aspirate culture medium 8–10 hr after transfection, and add 3 ml of complete medium.
6. Incubate the culture for an additional 48–72 hr to allow viral titer to increase. The viral titer reaches a maximum ~48 hr after transfection and is generally at least 30% of the maximum beyond 72 hr after transfection.

Alternative Method: Infecting packaging cells (Ping-Pong)

This method can be used to deliver the viral construct to the packaging cell line, an objective that can be accomplished by transfection, electroporation, or even infection (**Note:** Retro-X Q vectors can only be delivered by transfection). This method can also eliminate the need for selecting individual clones when making stable packaging cell lines (Parente & Wolfe, 1996). Alternatively, infect the packaging cells with virus obtained from another packaging cell line. Table II details the appropriate packaging cell lines to use for infection. A protocol for infection follows in Section VIII.

This approach produces high-titer virus for several reasons:

- More cells acquire the construct, and copy number is higher and more consistent (1–2 copies per cell per single round of infection depending upon titer of virus stock).
- Virus-producing clones derived from transduced cells are more stable than those derived from transfected cells (Parente & Wolfe, 1996).
- Allows the host-range of a vector to be changed.

Important Notes:

- This method requires previously transfected, virus-producing packaging cells.
- **You cannot infect cells that are already expressing the same or similar (eg. Amphi and 10A1) envelope protein. For example, virus produced from RetroPack™ PT67 cells cannot efficiently infect AmphiPack™-293 cells and vice versa.**
- Virus packaged in GP2-293 cells can be used to infect any other cell line depending on the envelope (pVSV-G, pEco, pAmphi or p10A1) that was cotransfected with the expression vector.
- Virus produced by EcoPack2-293 cells can only infect mouse and rat cells, such as RetroPack PT67 cells.

VII. Virus Production *continued*

B. Selecting Stable Virus-Producing Cell Lines

1. Prior to using antibiotics to establish stable cell lines, you must titrate antibiotic stocks to determine the optimal concentration for selection (see Appendix B). This procedure is commonly called a kill curve.
2. Plate transfected packaging cells in selection medium 24–36 hr after transfection.
3. Culture cells for one week with the appropriate antibiotic.
4. Isolate large, healthy colonies and transfer them to individual plates or wells.

Note: We generally isolate clones using cloning cylinders or cloning disks. The selected cell populations usually produce titers of $\sim 10^5$ cfu/ml. If you require higher titer clones, pick individual clones for propagation. Determine viral titer as described in Section VIII. You must screen 20–50 clones to isolate a clone of acceptably high titer. Once clones are isolated, withdraw antibiotic from the medium.

C. Concentrating Virus (VSV-G enveloped virions only, Burns *et al.*, 1994)

1. Remove cell debris and aggregated virus by low speed centrifugation for 5 min at 4°C.
2. Pellet the virus at 50,000 x g for 90 min at 4°C. Remove the supernatant.
3. Resuspend the virus to 0.5–1% of the original volume in TNE (See Additional Materials required), and incubate overnight at 4°C.
Note: If desired, perform a second round of ultracentrifugation (Steps 1–2).
4. Determine the viral titers of pre- and post-concentrated viral supernatants.
5. Infect target cells (Section IX.B.3).

D. Producing Virus from Stable Packaging Cell Clone (PT67)

1. Remove clone from liquid nitrogen and follow thaw procedures outlined in Section VI.B.
2. Culture the clone, until cell culture reaches the desired culture volume.
3. Retaining one plate for the continuation of the culture, plate the remaining cells at 60–80% confluency in the desired number of culture vessels.
4. Viral supernatants can then be harvested in 24 hr intervals until cells are no longer viable. Discard all cells once the virus has been harvested.

VII. Virus Production *continued*

E. Storage of Viral Stocks

1. Once viral supernatant has been collected, briefly centrifuge sample to remove cellular debris at 500 x g for 10 min. Pool all similar stocks at this time.
2. Aliquot cleared supernatant into single-use tubes to avoid multiple freeze-thaw cycles.
3. Store tubes at -70°C . No cryoprotectant is required.

Note: Avoid multiple freeze-thaw cycles, since titers can drop as much as 2–4 fold with each cycle (Higashikawa & Chang, 2001; Kwon *et al.*, 2003).

VIII. Determining Viral Titer

A. General Considerations

Determining the viral titer is necessary for three reasons:

- Confirmation that viral stocks are viable.
- Determination of the proper transduction conditions for your particular cell type by adjusting the MOI for the desired transduction efficiency. (i.e., control of copy number)

$$\text{MOI} = \text{No. of virus particles per target cell}$$

- Determination of the maximum number of target cells that can be infected for a given virus volume.

B. Procedure for Determining Viral Titer

1. Plate NIH 3T3 cells one day prior to beginning this procedure. Plate cells in 6-well plates at a density of $0.5\text{--}1 \times 10^5$ cells per well. Add 2 ml of medium per well.
2. Prepare 20 ml of complete medium and add 60 μl of 4 mg/ml polybrene.

Note: Polybrene is a polycation that reduces charge repulsion between the virus and the cellular membrane.

3. Collect virus-containing medium from packaging cells.
4. Filter medium through a 0.45- μm cellulose acetate or polysulfonic (low protein binding) filter. **Do not use a nitrocellulose filter** because nitrocellulose binds proteins in the retroviral membrane and destroys the virus. This is the viral stock.
5. Prepare six 10-fold serial dilutions as follows:
 - a. Add 1.35 ml of medium (Step 2) to each of six 1.5-ml microcentrifuge tubes.
 - b. Add 150 μl of virus-containing medium (Step 4) to the first tube. Mix.
 - c. Transfer 150 μl of viral stock dilution from tube 1 to tube 2. Continue serial dilutions by transferring 150 μl of each successive dilution to the next prepared tube.
6. Infect NIH 3T3 cells by adding 1 ml of the diluted virus medium (Step 5) to the wells. Final polybrene concentration will be 4 $\mu\text{g}/\text{ml}$ in ~ 3 ml.
7. If you used pLAPSN from the Retro-X™ System for virus production, stain cells after 48 hr by assaying for alkaline phosphatase expression. Use any standard alkaline phosphatase assay (Ausubel *et al.*, 1995).

For other vectors, subject cells to antibiotic selection 24 hr after infection for one week.

VIII. Determining Viral Titer *continued*

See Appendix B for Kill Curve information.

8. The viral titer corresponds to the number of colonies present at the highest dilution that contains colonies, multiplied by the dilution factor. For example, the presence of four colonies in the 10^6 dilution would represent a viral titer of 4×10^6 .

$$4 \text{ colony forming units (cfu)} \times 10^6 = 4 \times 10^6 \text{ cfu/ml}$$

For virus produced from RetroPack PT67, EcoPack2-293, AmphoPack-293, and GP2-293 cells, a good viral titer is $>10^6$ cfu/ml.

C. Alternative Methods

We recommend that you determine viral titer by infecting NIH 3T3 cells with serially diluted viral supernatants produced with a control vector such as pLAPSN, part of our Retro-X™ System (Cat. No. 631508). Infect both NIH 3T3 cells and your target cells. See Section IX for instructions on infecting NIH 3T3 cells. Infecting your target cell line will give you a rough, but rapid, estimation of infection success. You can use your cells of choice to determine viral titer (e.g., HeLa or Mink cells), but NIH 3T3 cells are widely accepted as the standard target cell for titrating retrovirus because of the efficiency at which these cells become infected. The same virus preparation can give different "apparent" titers on different cells lines due to differential receptor expression and cell cycle rates. For more information on determining viral titer, please refer to Ausubel, *et al.* (1995).

The method described in this manual is a standard gene transducing unit assay that measures the **functional** titer of a particular virus stock—the virus ability to infect is assayed. Another method is a drug-resistance colony assay, in which antibiotic selection of the infected cells gives rise to a countable number of colonies after roughly 10–14 days. Some variations of this method describe: a transduction, followed by a shorter selection period (3 days; Byun *et al.*, 1996), recently-infected target cells (Tafuro *et al.*, 1996; Miyao *et al.*, 1995), and in situ PCR (PRINS; Claudio *et al.*, 2001) with similar results. Other markers include LacZ, EGFP (Cashion *et al.*, 1999, Muldoon *et al.*, 1997), and luciferase.

Although it relates directly to the infectious viral particles, functional titer does not provide a consistent measurement of virion concentration because it depends upon the transduction efficiency of the cell line being used to determine titer. Therefore, direct quantitation for determining virus particle concentration may be more desirable. Also, physical quantitation lends itself for more high-throughput applications, such as screening of stable virus-producing clones for high-titer variants. Direct quantitation of virus concentration in supernatant does not rely on antibiotic selection and therefore all viruses, regardless of sequence can be quantitated. Methods for the direct quantitation

VIII. Determining Viral Titer *continued*

of virus particles include slot blots (Nelson *et al.*, 1998; Murdoch, *et al.*, 1997; Onodera, *et al.*, 1997) and PCR applied to viral supernatants (Quinn & Trevor, 1997; Morgan *et al.*, 1990). Reverse transcriptase activity has also been used (Goff *et al.*, 1981). Some have used protein production (encoded by the retroviral transgene) from packaging cells as a method for screening high titer clones, but this method is flawed because protein production does not correlate with the number of infectious virions (Tasaki *et al.*, 1997).

IX. Infecting Target Cells

A. General Considerations

The following protocols are general recommendations for infecting adherent cells, such as NIH 3T3 or HeLa. Use them as a starting point for determining optimal conditions for your experiments. If these protocols do not work for your cell type, please refer to Appendix C for alternative infection methods.

Important:

Multiple rounds of infection can improve your results by increasing the number of infected cells as well as increasing the copy number per cell.

Virus produced with the VSV-G envelope can be concentrated by ultracentrifugation to titers of up to 10^9 cfu/ml (See Section VII.C).

B. Infecting Target Cells

1. Plate the target cells 12–18 hr before infection, at a cell density of $1\text{--}2 \times 10^5$ per 60-mm plate.

If you will be using infected cells for a biological assay, ensure that the control cells are treated with an insert-free virus under identical conditions.

Note: The viral pre-integration complex enters the nuclei of actively dividing cells only.

2. For infection, collect medium from packaging cells and filter medium through a 0.45- μm cellulose acetate or polysulfonic (low protein binding) filter. **Do not use a nitrocellulose filter** because it binds proteins in the retroviral membrane and destroys the virus.

Optional: For VSV-G enveloped virus, you can concentrate virus as described in Section VII.C.

3. Add virus to target cells. Until you have determined the viral titer, use as much virus-containing medium as possible for the infection. Store remaining viral supernatant at -80°C .

IX. Infecting Target Cells *continued*

Notes:

- Titer will decrease ~2–4-fold per freeze-thaw cycle.
- The optimal final concentration of polybrene may need to be empirically determined but generally falls within a range of 2–12 $\mu\text{g/ml}$.
- Excessive exposure to polybrene (>24 hr) can be toxic to cells.

Alternatively, perform infections sequentially, ~12 hr apart. Doing so increases the efficiency of infection, but also increases copy number. Cellular receptors can be occupied by soluble envelope and/or non-functional virions. Therefore, to ensure that cellular receptors will be unoccupied by viral envelope, allow cells to rest for a minimum of 12 hr between each infection.

4. Add polybrene to a final concentration of 4–8 $\mu\text{g/ml}$.
5. Replace medium with fresh medium after 24 hr of incubation.
6. To determine the efficiency of infection, subject a small subpopulation of cells to antibiotic treatment. The infected cells should be used for experiments or for selection as soon as possible, but not earlier than 24 hr after the last infection.

The growth of some target cells is strongly affected by media conditioned by the packaging cells. You can take certain precautions to avoid an adverse effect induced by the packaging cell-derived supernatants:

- Dilute virus-containing media at least 2-fold with fresh medium.
- Expose target cells to the virus for 4–6 hr and then replace with fresh medium.
- For cells that prove more difficult to infect, please see references located in Appendix C.

X. Troubleshooting Guide

A. Cloning

DNA does not cut as expected	Incomplete digest: repeat digest with more enzyme, a different enzyme lot, or for a longer period of time.
Low yield of plasmid	Retroviral constructs use a low copy pBR322 ori. Grow more liquid culture and purify using low-copy purification procedures.
Plasmid is difficult to grow or clone.	Plasmid may rearrange due to presence of LTR's. Switch to alternate <i>E. coli</i> strain for unstable DNA sequences.

B. Packaging Cells

Poor viability upon thawing	Improper thawing procedures: follow thawing procedures in Section VI.B. Improper culture medium: all packaging cell lines will grow in DMEM + 10% FBS Improper tissue culture plasticware: use collagen I-coated plates to aid adherence during initial seeding.
Slow growth	Improper culture medium: all packaging cell lines will grow in DMEM + 10% FBS. Improper incubator conditions: grow cells at 37°C in humidified incubator with 5–10% CO ₂ .
Cells do not attach to plate	Improper culture medium: all packaging cell lines will grow in DMEM + 10% FBS. Improper tissue culture plasticware: use collagen I-coated plates to aid adherence during initial seeding.
Cells appear morphologically different	Subclone parental cell line.
Cannot select for packaging	Incorrect amount of antibiotic: we do not recommend reselecting for packaging function.

X. Troubleshooting Guide *continued*

C. Virus Production

Poor Transfection efficiency Cells are overly confluent: plate fewer cells (60–80% confluency, $1\text{--}2 \times 10^6$ cells/60mm).
Transfection is toxic to cells: Optimize DNA and transfection reagent amounts and exposure time.

Assaying for positive cells too early: wait 48 hr after transfection for maximal gene expression to determine efficiency.

Low titer ($<10^5$ cfu/ml) Poor transfection efficiency: optimize transfection.
Concentrate virus if using VSV-G.

Truncated viral RNA: check sequence for presence of poly(A) between LTRs.

Virus harvested too early: harvest virus 48–72 hr after transfection.

Vector too large (The limit of packaging function is 8.3 kb from LTR to LTR). Concentrate virus for large vectors or reduce size of inserts.

Low virus production from cell population (PT67): Pick and screen for stable, higher-titer clones.

No polybrene added during titration: add polybrene (4–8 $\mu\text{g/ml}$) to viral supernatant.

Virus exposed to multiple freeze-thaw cycles: each cycle drops the titer approximately 2–4 fold. Limit the number of freeze-thaws.

Sub-optimal selection procedure during titration: perform an antibiotic kill curve on titration targets prior to titration.

X. Troubleshooting Guide *continued*

D. Infection of Target Cells

Poor infection efficiency

Low titer: see above section.

Infection protocol not optimized: see Appendix C for references for optimizing transduction protocols.

Target cells not dividing: plate cells at lower confluency, activate with mitogen, or use another method to induce cell division.

Optimize culture conditions for targets prior to infection.

Target cell viability poor during infection

Packaging cell line-conditioned media may be affecting cell growth: dilute viral medium or shorten exposure time to viral supernatant.

Excessive exposure to polybrene: optimize amount of polybrene (titrate) or shorten exposure time to viral supernatant.

Low infection efficiency (See Section D, above).

Low expression level

Possible promoter inactivation: split cells, activate with mitogen, treat cells with 5-azacytidine.

Choose a tissue-specific promoter.

Poor cell viability: check growth parameters.

XI. References

- Adeno-X Expression System (2000) Clontechiques **XV**(1):8–10.
- Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. M., Seidman, J. G., Smith, J. A. & Struhl, K., Eds. (1995) *Current Protocols in Molecular Biology*. (John Wiley & Sons, NY).
- Barton, G. M. & Medzhitov, R. (2002) Retroviral delivery of small interfering RNA into primary cells. *Proc. Natl. Acad. Sci. USA* **99**(23):14943–14945.
- Brummelkamp, T. R., Bernards, R. & Agami, R. (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. *Cancer Cell* **2**(3):243–247.
- Burns, J. C., Friedmann, T., Driever, W., Burrascano, M. & Yee, J.-K. (1993) Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. *Proc. Natl. Acad. Sci. USA* **90**:8033–8037.
- Byun, J., Kim, J. M., Kim, S. H., Yim J., Robbins, P. D. & Kim, S. (1996) A simple and rapid method for the determination of recombinant retrovirus titer by G418 selection. *Gene Ther.* **3**:1018–1020.
- Cashion, L. M., Bare, L. A., Harvey, S., Trinh, Q., Zhu, Y. & Devlin, J. J. (1999) Use of enhanced green fluorescent protein to optimize and quantitate infection of target cells with recombinant retroviruses. *Biotechniques* **26**: 924–930.
- Claudio, P. P., Cinti, C. & Giordano, A. (2001) Application of the primer in situ DNA synthesis (PRINS) technique to titer recombinant virus and evaluation of the efficiency of viral transduction. *Anal. Biochem.* **291**:96–101.
- Coffin, J. M. & Varmus, H. E., Ed. (1996) *Retroviruses* (Cold Spring Harbor Laboratory Press, NY).
- Devroe, E. & Silver, P. A. (2002) Retrovirus-delivered siRNA. *BMC Biotechnol.* **2**(1):15.
- Emi, N., Friedmann, T. & Yee, J.-K. (1991) Pseudotyped formation of murine leukemia virus with G protein of vesicular stomatitis virus. *J. Virol.* **65**:1202–1207.
- Freshney, R. I. (2000) *Culture of Animal Cells*, Fourth Edition (Wiley-Liss, NY).
- Goff, S., Traktman, P. & Baltimore D. (1981) Isolation and properties of Moloney murine leukemia virus mutants: use of a rapid assay for release of virion reverse transcriptase. *J. Virol.* **38**:239–248.
- Hawley, R. G., Lieu, F. H. L., Fong, A. Z. C., & Hawley, T. S. (1994) Versatile retroviral vectors for potential use in gene therapy. *Gene Ther.* **1**:136–138.
- Hemann, M. T., Fridman, J. S., Zilfou, J. T., Hernando, E., Paddison, P. J., Cordon-Cardo, C., Hannon, G. J. & Lowe, S. W. (2003) An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. *Nat. Genet.* **33**(3):396–400.
- Hilberg, F. (1987) Functional analysis of a retroviral host-range mutant: altered long terminal repeat sequences allow expression in embryonal carcinoma cells. *Proc. Natl. Acad. Sci. USA* **84**:5232–5236.
- Higashikawa, F. & Chang L. (2001) Kinetic Analysis of stability of simple and complex retroviral vectors. *Virology* **280**:124–131.
- Jackson, R. J., Howell M. T. & Kaminski, A. (1990) The novel mechanism of initiation of picornavirus RNA translation. *Trends Biochem. Sci.* **15**:477–483.
- Jang, S. K., Krausslich, H. G., Nicklin, M. J., Duke, G. M., Palmenberg, A. C. & Wimmer, E. (1988) A segment of the 5' untranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. *J. Virol.* **62**:2636–2643.
- Kozak, M. (1987) At least six nucleotides preceding the AUG initiator codon enhances translation in mammalian cells. *J. Mol. Biol.* **196**:947–950.

XI. References *continued*

- Kwon, Y. J., Hung, G., Anderson, W.F., Peng, C.A. & Yu, H. (2003) Determination of infectious retrovirus concentration from colony-forming assay with quantitative analysis. *J. Virol.* **77**:5712–5720.
- Mann, R., Mulligan, R. C. & Baltimore, D. (1983) Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. *Cell* **33**:153–159.
- Miller, A. D. (1996) Cell-surface receptors for retroviruses and implications for gene transfer. *Proc. Natl. Acad. Sci. USA* **93**:11407–11413.
- Miller, A. D. & Baltimore, C. (1986) Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. *Mol. Cell. Biol.* **6**(8):2895–2902.
- Miller, A. D. & Chen, F. (1996) Retrovirus packaging cells based on 10A1 murine leukemia virus for production of vectors that use multiple receptors for cell entry. *J. Virol.* **70**(8):5564–5571.
- Miller, D. G. & Miller A. D. (1994) A family of retroviruses that utilize related phosphate transporters for cell entry. *J. Virol.* **68**:8270–8276.
- Miyao, Y., Shimizu, K., Tamura, M., Yamada, M., Tamura, K., Nakahira, K., Kuriyama, S., Hayakawa, T. & Ikenaka, K. (1995) A simplified general method for determination of recombinant retrovirus titers. *Cell Struct. Funct.* **20**:177–183.
- Morgan, R. A., Cornetta, K. & Anderson W. F. (1990) Applications of the polymerase chain reaction in retroviral-mediated gene transfer and the analysis of gene-marked human TIL cells. *Hum. Gene Ther.* **1**:135–149.
- Morgenstern, J. P. & Land, H. (1990) Advanced mammalian gene transfer: high titer retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. *Nucleic Acids Res.* **18**:3587–3590.
- Muldoon, R. R., Levy, J. P., Kain S. R., Kitts, P. A. & Link, C. J. Jr. (1997) Tracking and quantitation of retroviral-mediated transfer using a completely humanized, red-shifted green fluorescent protein gene. *Biotechniques* **22**:162–167.
- Murdoch, B., Pereira, D. S., Wu, X., Dick, J. E. & Ellis, J. (1997) A rapid screening procedure for the identification of high-titer retrovirus packaging clones. *Gene Ther.* **4**:744–749.
- Nelson, D. M., Wahlfors, J. J., Chen, L., Onodera, M. & Morgan, R. A. (1998) Characterization of diverse viral vector preparations, using a simple and rapid whole-virion dot-blot method. *Hum. Gene Ther.* **9**:2401–2405.
- Onodera, M., Yachie, A., Nelson, D. M., Welchlin, H., Morgan, R. A. & Blaese, R. M. (1997) A simple and reliable method for screening retroviral producer clones without selectable markers. *Hum. Gene Ther.* **8**:1189–1194.
- Parente, M. K. & Wolfe, J. H. (1996) Production of increased titer retrovirus vectors from stable producer cell lines by superinfection and concentration. *Gene Ther.* **3**:756–760.
- Pear, W. S., Nolan, G. P., Scott, M. L. & Baltimore, D. (1993) Production of high-titer helper-free retroviruses by transient transfection. *Proc. Natl. Acad. Sci. USA* **90**(18):8392–8396.
- Qin, X. F., An, D. S., Chen, I. S. & Baltimore, D. (2003) Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. *Proc. Natl. Acad. Sci. USA* **100**(1):183–8.
- Quinn, T. P. & Trevor, K. T. (1997) Rapid quantitation of recombinant retrovirus produced by packaging cell clones. *Biotechniques* **23**:1038–1044.
- Sambrook, J. & Russell, D.W. (2001) *Molecular Cloning: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY).
- Tafuro, S., Zentilin, L., Falaschi, A. & Giacca, M. (1996) Rapid retrovirus titration using competitive polymerase chain reaction. *Gene Ther.* **3**:679–684.

XI. References *continued*

Tasaki, K., Yoshida, Y., Tagawa, M., Takenaga, K., Asano, T., Ochiai, T., Isono, K., Kouzu, T., Saisho, H. & Sakiyama, S. (1997) Discordant production of released exogenous protein and infectious virions from retrovirus-packaging cells used for gene transduction. *Anticancer Res.* **17**:4415–4417.

Xia, H., Mao, Q., Paulson, H. L. & Davidson, B. L. (2002) siRNA-mediated gene silencing in vitro and in vivo. *Nat. Biotechnol.* **20**:1006–1010.

Yap, M. W., Kingsman, S. M. & Kingsman, A. J. (2000) Effects of stoichiometry of retroviral components on virus production. *J. Gen. Virol.* **81**:2195–2202.

Yee, J.-K., Friedmann, T. & Burns, J. C. (1994) Generation of high-titer pseudotyped retroviral-vectors with very broad host range. *Methods Cell Biol.* **43**:99–112.

Appendix A: Culture Plate Conversions

TABLE III: CULTURE PLATE CONVERSION

Size of Plate	Growth Area (cm ²)	Relative area*	Recommended Volume
96 well	0.32	0.04 X	200 µl
24 well	1.88	0.25 X	500 µl
12 well	3.83	0.5 X	1.0 ml
6 well	9.4	1.2 X	2.0 ml
35 mm	8.0	1.0 X	2.0 ml
60 mm	21	2.6 X	5.0 ml
10 cm	55	7 X	10.0 ml
Flasks	25	3 X	5.0 ml
	75	9 X	12.0 ml

* Relative area is expressed as a factor of the growth area of a 35-mm culture plate.

Appendix B: Titration of Antibiotic Stocks (Kill Curves)

Prior to using G418, hygromycin or puromycin to establish stable packaging cell lines, it is important to titrate your selection agent stocks to determine the optimal concentration for selection with the chosen cell line. This is also important because of lot-to-lot variation in the potency of these drugs. Therefore, you should titrate each new lot of antibiotic to determine the optimal concentration. We recommend that you perform two experiments for each drug: (1) a titration to determine the optimal drug concentration, and (2) an experiment to determine the optimal plating density.

1. Titrate at fixed cell density.

- a. Plate 2×10^5 cells in each of six 10-cm tissue culture dishes containing 10 ml of the appropriate complete medium plus varying amounts (0, 50, 100, 200, 400, 800 $\mu\text{g/ml}$) of hygromycin or G418. For puromycin, add the drug at 0, 1, 2.5, 5, 7.5, and 10 $\mu\text{g/ml}$.
- b. Incubate the cells for 10–14 days, replacing the selective medium every four days (or more often if necessary).
- c. Examine the dishes for viable cells every two days.

For selecting stable transformants, use the lowest concentration that begins to give massive cell death in ~ 5 days and kills all the cells within two weeks.

2. Determine optimal plating density.

Once you have determined the optimal drug concentration, determine the optimal plating density by plating cells at several different densities in the presence of a constant amount of drug. If cells are plated at too high a density, they will reach confluency before the selection takes effect. Optimal plating density is dependent on population doubling time and cell surface area. For example, cells that double rapidly have a lower optimal plating density than cells that double slowly.

- a. Plate cells at several different densities in each of six 10-cm tissue culture dishes containing 10 ml of the appropriate selective medium. Suggested densities (cells/10-cm dish): 5×10^6 , 1×10^6 , 5×10^5 , 2×10^5 , 1×10^5 , and 5×10^4 .
- b. Incubate the cells for 5–14 days, replacing the selective medium every four days.
- c. Examine the dishes for viable cells every two days.

For selecting stable transfectants, use a plating density that allows the cells to reach $\sim 80\%$ confluency before massive cell death begins (at about day 5). This is the cell density at which cells should be plated for selection of stable transfectants.

Appendix C: Additional Viral Infection Methods

These references are provided for fine-tuning your transduction protocols to achieve the desired infection frequency in target cells. This list is not intended to be comprehensive. These protocols will work for a wide range of cell types; however you must determine which works best for your targets. While each technique can provide modest increases in efficiency, they may be combined to create an additive effect. For ease of analysis, we recommend our retroviral vectors that express our Living Colors™ fluorescent proteins for detection and quantitation of gene transfer efficiency during testing.

A. Transduction of cells at 32°C: Decrease in temperature increases viral half-life during transduction

Bunnell, B. A., Muul, L. M., Donahue, R. E., Blaese, R. M., Morgan, R. A. (1995) High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. *Proc. Natl. Acad. Sci. USA* **92**(17):7739–7743.

Zhou, P., Lee, J., Moore, P., Brasky, K. M. (2001) High-efficiency gene transfer into rhesus macaque primary T lymphocytes by combining 32 degrees C centrifugation and CH-296-coated plates: effect of gene transfer protocol on T cell homing receptor expression. *Hum. Gene Ther.* **12**(15):1843–1855.

Kotani, H., Newton, P. B. 3rd, Zhang, S., Chiang, Y. L., Otto, E., Weaver, L., Blaese, R. M., Anderson, W. F. & McGarrity, G. J. (1994) Improved methods of retroviral vector transduction and production for gene therapy. *Hum. Gene Ther.* **5**(1):19–28.

Higashikawa, F. & Chang, L. (2001) Kinetic analyses of stability of simple and complex retroviral vectors. *Virology* **280**(1):124–131.

B. Centrifugation during transduction (Spinoculation): believed to counteract diffusion of virus when binding target cells

Bunnell, B. A., Muul, L. M., Donahue, R. E., Blaese, R. M. & Morgan, R. A. (1995) High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. *Proc. Natl. Acad. Sci. USA* **92**(17):7739–7743.

Ohkubo, T., Barcena, A., Smith, C. A., Harrison, M. R. & Muench, M. O. (2001) High-efficiency retroviral transduction of fetal liver CD38-CD34++ cells: implications for in utero and ex utero gene therapy. *Fetal Diagn. Ther.* **16**(5):299–307.

Movassagh, M., Boyer, O., Burland, M. C., Leclercq, V., Klatzmann, D. & Lemoine F. M. (2000) Retrovirus-mediated gene transfer into T cells: 95% transduction efficiency without further in vitro selection. *Hum. Gene Ther.* **11**(8):1189–1200.

Bahnson, A. B., Dunigan, J. T., Baysal, B. E., Mohny, T., Atchison, R. W., Nimgaonkar, M. T., Ball, E. D. & Barranger, J. A. (1995) Centrifugal enhancement of retroviral mediated gene transfer. *J. Virol. Methods* **54**:131–143.

C. Precipitation to increase titer (concentration)

Pham, L., Ye, H., Cosset, F. L., Russell, S. J. & Peng, K. W. (2001) Concentration of viral vectors by co-precipitation with calcium phosphate. *J. Gene Med.* **3**(2):188–194.

Darling, D., Hughes, C., Galea-Lauri, J., Gaken, J., Trayner, I. D., Kuiper, M. & Farzaneh, F. (2000) Low-speed centrifugation of retroviral vectors absorbed to a particulate substrate: a highly effective means of enhancing retroviral titre. *Gene Ther.* **7**(11):914–923.

Hughes, C., Galea-Lauri, J., Farzaneh, F. & Darling, D. (2001) Streptavidin paramagnetic

Appendix C: Additional Viral Infection Methods *continued*

particles provide a choice of three affinity-based capture and magnetic concentration strategies for retroviral vectors. *Mol. Ther.* **3**(4):623–630.

D. Precipitation (during transduction): facilitates greater contact between the target cells and virions

Le Doux, J. M., Landazuri, N., Yarmush, M. L. & Morgan, J. R. (2001) Complexation of retrovirus with cationic and anionic polymers increases the efficiency of gene transfer. *Hum. Gene Ther.* **12**(13):1611–1621.

Morling, F. J. & Russell, S. J. (1995) Enhanced transduction efficiency of retroviral vectors coprecipitated with calcium phosphate. *Gene Ther.* **2**(7):504–508.

Hennemann, B., Chuo, J. Y., Schley, P. D., Lambie, K., Humphries, R. K. & Eaves, C. J. (2000) High-efficiency retroviral transduction of mammalian cells on positively charged surfaces. *Hum. Gene Ther.* **11**(1):43–51.

E. Increase transduction rate by phosphate depletion: results in up regulation of GLVR-1 and GLVR-2 (RAM1) receptors (for amphotropic or 10A1 pseudotyped virus)

Bunnell, B. A., Muul, L. M., Donahue, R. E., Blaese, R. M. & Morgan, R. A. (1995) High-efficiency retroviral-mediated gene transfer into human and nonhuman primate peripheral blood lymphocytes. *Proc. Natl. Acad. Sci. USA* **92**(17):7739–7743.

Zhou, P., Lee, J., Moore P, Brasky K. M. (2001) High-efficiency gene transfer into rhesus macaque primary T lymphocytes by combining 32 degrees C centrifugation and CH-296-coated plates: effect of gene transfer protocol on T cell homing receptor expression. *Hum. Gene Ther.* **12**(15):1843–1855.

F. Flow through transduction: concentrating cells and virus together in small culture systems

Pan, D., Shankar, R., Stroncek, D. F. & Whitley, C. B. (1999) Combined ultrafiltration-transduction in a hollow-fiber bioreactor facilitates retrovirus-mediated gene transfer into peripheral blood lymphocytes from patients with mucopolysaccharidosis type II. *Hum. Gene Ther.* **10**(17):2799–2810.

Chuck, A. S. & Palsson, B. O. (1996) Consistent and high rates of gene transfer can be obtained using flow-through transduction over a wide range of retroviral titers. *Hum. Gene Ther.* **7**(6):743–750.

G. Addition of fibronectin: adhesion domains within fibronectin allow binding to both target cells and virions to facilitate co-localization

Zhou, P., Lee, J., Moore, P. & Brasky, K. M. (2001) High-efficiency gene transfer into rhesus macaque primary T lymphocytes by combining 32 degrees C centrifugation and CH-296-coated plates: effect of gene transfer protocol on T cell homing receptor expression. *Hum. Gene Ther.* **12**(15):1843–1855.

Moritz, T., Dutt, P., Xiao, X., Carstanjen, D., Vik, T., Hanenberg, H. & Williams, D. A. (1996) Fibronectin improves transduction of reconstituting hematopoietic stem cells by retroviral vectors: evidence of direct viral binding to chymotryptic carboxy-terminal fragments. *Blood* **88**(3):855–862.

Hanenberg, H., Xiao, X. L., Dilloo, D., Hashino, K., Kato, I. & Williams, D. A. (1996) Co-localization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells. *Nat. Med.* **2**(8):876–882.

Appendix C: Additional Viral Infection Methods *continued*

Bajaj, B., Lei, P. & Andreadis, S.T. (2001) High efficiencies of gene transfer with immobilized recombinant retrovirus: kinetics and optimization. *Biotechnol. Prog.* **17**(4):587–596.

H. Cocultivation of target cells and packaging cells: Allows targets to be continuously in contact with freshly-produced viral supernatant

Casal, M. L. & Wolfe, J. H. (1997) Amphotropic and ecotropic retroviral vector viruses transduce midgestational murine fetal liver cells in a dual-chambered cocultivation system. *Gene Ther.* **4**(1):39–44.

Germeraad, W. T., Asami, N., Fujimoto, S., Mazda, O. & Katsura, Y. (1994) Efficient retrovirus-mediated gene transduction into murine hematopoietic stem cells and long-lasting expression using a transwell coculture system. *Blood* **84**(3):780–788.

I. Use of cationic liposomes: Enhance virus-to-cell fusion

Kaneko, Y. & Tsukamoto, A. (1996) Cationic liposomes enhance retrovirus-mediated multinucleated cell formation and retroviral transduction. *Cancer Lett.* **105**(1):39–44.

Porter, C. D., Lukacs, K.V., Box, G., Takeuchi, Y. & Collins, M. K. (1998) Cationic liposomes enhance the rate of transduction by a recombinant retroviral vector in vitro and in vivo. *J. Virol.* **72**(6):4832–4840.

J. Use of histone deacetylase inhibitors to increase titer: Relieves repression of viral expression by hyperacetylation of histones

Chen, W.Y., Bailey, E. C., McCune, S. L., Dong, J.Y. & Townes, T. M. (1997) Reactivation of silenced, virally transduced genes by inhibitors of histone deacetylase. *Proc. Natl. Acad. Sci. USA* **94**:5798–5803.

Tobias, C. A., Kim, D. & Fischer, I. (2000) Improved recombinant retroviral titers utilizing trichostatin A. *Biotechniques* **29**:884–890.

Notice to Purchaser

Notice to Purchaser

Clontech products are to be used for research purposes only. They may not be used for any other purpose, including, but not limited to, use in drugs, *in vitro* diagnostic purposes, therapeutics, or in humans. Clontech products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products or to provide a service to third parties without written approval of Clontech Laboratories, Inc.

For Research Use Only. Not for Use in Humans.

Use of the Retro-X™ Universal Packaging System, AmphoPack™ 293, and EcoPack™ 2-293 are covered by U.S. Patent No. 5,858,740 and are limited to use solely for research purposes. Please contact GBP IP LLC for a license to use these products for commercial purposes.

The RetroPack PT67 Cell Line is covered under U.S. Patent No. 5,766,945, which has been assigned to the Fred Hutchinson Cancer Research Center. Retroviral vectors are sold under license from Fred Hutchinson Cancer Research Center. Rights to use this product are limited to research only. No other rights are conveyed. Inquiry into the availability of a license to broader rights or the use of this product for commercial purposes should be directed to Fred Hutchinson Cancer Research Center, Technology Transfer Office, 1100 Fairview Avenue North, J6-200, Seattle, WA 98109. Purchase of this product does not grant rights to:

1. offer the materials or any derivatives thereof for resale;
2. to distribute or transfer the materials or any derivatives thereof to third parties.

Use of the MSCV Retroviral Expression System is exclusively licensed from Robert G. Hawley, Ph.D. Academic research institutions are granted an automatic license with the purchase of this product to use the MSCV Retroviral Expression System only for internal, academic research purposes. This limitation expressly excludes the right to sell or otherwise transfer the MSCV system or its component parts to third parties. All other users and purchasers are required to obtain a license from Clontech prior to purchasing these reagents or using them for any purpose. For information on licensing please contact a licensing representative by phone at 650.919.7320 or by e-mail at licensing@clontech.com.

Use of the Pantropic Retroviral Expression System and the Retro-X™ Universal Packaging System are licensed from Pangenix and are covered under U.S. Patent Nos. 5,512,421 and 5,670,354. Rights to use this product are limited to nonhuman research only and use of the patented technology in domestic ungulates is expressly prohibited. No other rights are conveyed. Inquiry into the availability of a license for commercial purposes should be directed to Jane C. Burns, M.D., Pangenix, 6505 El Camino del Teatro, La Jolla, CA 92037.

VSV-G is licensed from Pangenix and its use is covered under U.S. Patent Nos. 5,512,421 and 5,670,354. Rights to use this product are limited to nonhuman research only and use of the patented technology in domestic ungulates is expressly prohibited. No other rights are conveyed. Inquiry into the availability of a license for commercial purposes should be directed to Jane C. Burns, M.D., Pangenix, 6505 El Camino del Teatro, La Jolla, CA 92037.

DsRed-Monomer: This product is covered under U.S. Patent No. 7,250,298.

Polybrene® is a registered trademark of Abbott Laboratories, Inc.

NucleoSpin® and NucleoBond® are registered trademarks of MACHEREY-NAGEL GmbH & Co. KG.

Zeocin™ is a trademark of CAYLA.

Clontech, the Clontech Logo and all other trademarks are the property of Clontech Laboratories, Inc., unless noted otherwise. Clontech is a Takara Bio Company. ©2010 Clontech Laboratories, Inc.